Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

21. Diclofenac: public consultation on availability as a pharmacy medicine

Diclofenac: public consultation on availability as a pharmacy medicine Diclofenac: public consultation on availability as a pharmacy medicine - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Diclofenac: public consultation on availability as a pharmacy medicine Public consultation launched on the continued availability of oral diclofenac as a pharmacy (P) medicine and on risk-minimisation measures advised by the Commission on Human Medicines. Published 11 December 2014 From (...) : Therapeutic area: Article date: August 2013 We have launched a public consultation on the continued availability of oral diclofenac as a pharmacy (P) medicine and in particular on risk-minimisation measures advised by the Commission on Human Medicines. Any comments can be emailed to ; alternatively they may be addressed to: Colette McCreedy, Self Medication Specialist and Unit Manager, MHRA, 3rd Floor, 151 Buckingham Palace Road, London SW1W 9SZ. Comments must arrive no later than 28 October 2013

2013 MHRA Drug Safety Update

22. Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder

Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder UTCAT2225, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Topical Administration of Diclofenac is as Effective as Systemic Administration in Alleviating Ailments of Temporomandibular Joint Disorder Clinical Question In a patient suffering from Temporomandibular Joint Disorder (...) , is topical administration of treatment as effective when compared to systemic administration of treatment in alleviating ailments? Clinical Bottom Line Topical administration of diclofenac is as effective as systemic administration in alleviating ailments of temporomandibular joint disorder. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Di Rienzo/2004 36 adult patients diagnosed with dysfunction of the TMJ

2012 UTHSCSA Dental School CAT Library

23. Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions

Safety profile of topical diclofenac: a meta-analysis of blinded, randomized, controlled trials in musculoskeletal conditions Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

24. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. (Abstract)

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective NSAIDs plus a proton-pump inhibitor (PPI) have similar upper gastrointestinal outcomes, but risk of clinical outcomes across the entire gastrointestinal tract might be lower with selective drugs than with non-selective drugs. We aimed to compare risk of gastrointestinal (...) events associated with celecoxib versus diclofenac slow release plus omeprazole.We undertook a 6-month, double-blind, randomised trial in patients with osteoarthritis or rheumatoid arthritis at increased gastrointestinal risk at 196 centres in 32 countries or territories. Patients tested negative for Helicobacter pylori and were aged 60 years and older or 18 years and older with previous gastroduodenal ulceration. We used a computer-generated randomisation schedule to assign patients in a 1:1 ratio

2010 Lancet Controlled trial quality: predicted high

25. Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries

Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries Kuehl KS CRD summary The review concluded that diclofenac epolamine (...) topical patch 1.3% significantly reduced pain in patients with soft tissue injuries and was well tolerated. Given the potential for bias in the review and the limitations of the small evidence base (such as uncertain quality and heterogeneity), the author's conclusions should be interpreted with caution. Authors' objectives To assess the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in the treatment of patients with acute pain due to soft tissue injuries. Searching MEDLINE

2010 DARE.

26. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness

Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness Tsakonas E, Argaez C Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tsakonas E, Argaez C. Topical diclofenac for the treatment of musculoskeletal pain unrelated to osteoarthritis: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions The studies reviewed for this report suggest that in general, topical diclofenac (in gel and patch formulations), is safe and effective

2009 Health Technology Assessment (HTA) Database.

27. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac (Abstract)

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac Nonsteroidal anti-inflammatory drugs (NSAIDs) cause lower gastrointestinal (GI) clinical events such as bleeding. Cyclo-oxygenase (COX)-2 selective inhibitors decrease upper GI events, but no prospective trial has prespecified assessment of lower GI clinical events.Patients >or=50 years old with osteoarthritis (...) or rheumatoid arthritis were randomly assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd). Lower GI clinical events, confirmed by a blinded adjudication committee, included perforation or obstruction requiring hospitalization or bleeding (gross or occult rectal bleeding without upper GI cause associated with hypotension, orthostatic changes in heart rate [>20 beats per minute] or blood pressure [>20 mmHg systolic or >10 mmHg diastolic], hemoglobin drop >or=2 g/dl, or transfusion; or observed

2008 EvidenceUpdates Controlled trial quality: predicted high

28. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) (Abstract)

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II) A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032 (...) ) or diclofenac 75 mg twice daily (n = 2054). Use of gastroprotective agents and low-dose aspirin was allowed. The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs). General safety was also assessed, including adjudicated thrombotic cardiovascular event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).Mean (SD; maximum) duration of treatment was 19.3

2008 EvidenceUpdates Controlled trial quality: predicted high

29. Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain

Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Article Text Therapeutics Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain

2008 Evidence-Based Medicine

30. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. (Abstract)

Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. We aimed to investigate whether the addition of non-steroidal anti-inflammatory drugs or spinal manipulative therapy, or both, would result in faster recovery for patients with acute low back pain receiving recommended first-line care.240 patients with acute low back pain who had seen their general practitioner and had been (...) given advice and paracetamol were randomly allocated to one of four groups in our community-based study: diclofenac 50 mg twice daily and placebo manipulative therapy (n=60); spinal manipulative therapy and placebo drug (n=60); diclofenac 50 mg twice daily and spinal manipulative therapy (n=60); or double placebo (n=60). The primary outcome was days to recovery from pain assessed by survival curves (log-rank test) in an intention-to-treat analysis. This trial was registered with the Australian

2007 Lancet Controlled trial quality: predicted high

31. Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Full Text available with Trip Pro

Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Topical diclofenac improved pain and physical function with no systemic side effects in primary osteoarthritis of the knee Article Text

2006 Evidence-Based Medicine

32. Single dose oral diclofenac for postoperative pain. Full Text available with Trip Pro

Single dose oral diclofenac for postoperative pain. Diclofenac is a benzene-acetic acid derivative that acts, like other NSAIDs, by inhibiting cyclo-oxygenase isoforms that mediate the body's production of the prostaglandins implicated in pain and inflammation. Diclofenac is widely available as a sodium or potassium salt. Diclofenac potassium tablets are known as 'immediate-release' diclofenac as absorption takes place in the gastrointestinal tract whereas 'delayed-release' (enteric-coated (...) ) diclofenac tablets resist dissolution until reaching the duodenum. An existing review showed that diclofenac was an effective treatment for acute postoperative pain but did not address the distinction between potassium and sodium salts due to lack of data. The aim of this update is to gather and add appropriate information published subsequently and, data permitting, examine any potential differences between the two different diclofenac formulations.To assess single dose oral diclofenac for the treatment

2004 Cochrane

33. The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis

The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis Pope J E, Prashker (...) M, Anderson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of combination therapy with diclofenac (50 mg) and misoprostol (Arthrotec; 200 microg twice daily) for the treatment of patients with symptomatic

2004 NHS Economic Evaluation Database.

34. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

2003 NHS Economic Evaluation Database.

35. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial

Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial von Scheele B, Pena B, Wong J, Niculescu L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Valdecoxib (20 mg once daily), an oral cyclooxygenase (COX)-2-specific inhibitor, was compared with diclofenac (75 mg twice daily), a non-specific non-steroidal anti-inflammatory drug (NSAID

2003 NHS Economic Evaluation Database.

36. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Full Text available with Trip Pro

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Current guidelines recommend that patients at risk for ulcer disease who require treatment for arthritis receive nonsteroidal antiinflammatory drugs (NSAIDs) that are selective for cyclooxygenase-2 or the combination of a nonselective NSAID with a proton-pump inhibitor. We assessed whether celecoxib would be similar to diclofenac plus omeprazole in reducing the risk (...) of recurrent ulcer bleeding in patients at high risk for bleeding.We studied patients who used NSAIDs for arthritis and who presented with ulcer bleeding. After their ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either 200 mg of celecoxib twice daily plus daily placebo or 75 mg of diclofenac twice daily plus 20 mg of omeprazole daily for six months. The end point was recurrent ulcer bleeding.In the intention-to-treat analysis, which included 287

2002 NEJM Controlled trial quality: uncertain

37. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac Full Text available with Trip Pro

A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac Morant S V, Shield M J, Davey P G, MacDonald T M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The misoprostol-diclofenac fixed combination preparation was compared with diclofenac and other prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), to investigate the association between NSAIDs and admission to hospital for upper gastrointestinal (GI) haemorrhage and perforation and other upper GI events. Type of intervention Other: Secondary care. Economic study type Cost-effectiveness analysis. Study

2002 NHS Economic Evaluation Database.

38. Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain

Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Tarricone R, Martelli E, Parazzini F, Darba J, Le Pen C, Rovira J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two drug therapies, nimesulide and diclofenac, for the treatment of osteoarthritis (OA). Both drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), which although beneficial in reducing pain and inflammation, may result in potentially serious consequences in terms

2001 NHS Economic Evaluation Database.

39. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. (Abstract)

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated production of gastrointestinal-protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX (...) inhibitor.655 patients with adult-onset rheumatoid arthritis of at least 6 months' duration were randomly assigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks. Anti-inflammatory and analgesic activity and tolerability were assessed at baseline, every 4 weeks, and at week 24. We assessed gastrointestinal safety by upper-gastrointestinal endoscopy within 7 days of the last treatment dose at centres where the procedure was available. Analysis was by intention-to-treat

2000 Lancet Controlled trial quality: predicted high

40. Single dose oral ibuprofen and diclofenac for postoperative pain. Full Text available with Trip Pro

Single dose oral ibuprofen and diclofenac for postoperative pain. Ibuprofen and diclofenac are two widely used non-steroidal anti-inflammatory (NSAID) analgesics. It is therefore important to know which drug should be recommended for postoperative pain relief. This review seeks to compare the relative efficacy of the two drugs, and also considers the issues of safety and cost.To assess the analgesic efficacy of ibuprofen and diclofenac in single oral doses for moderate to severe postoperative (...) allocation to treatment groups which compared either ibuprofen or diclofenac with placebo.Data were extracted by two independent reviewers, and trials were quality scored. Summed pain relief or pain intensity difference over four to six hours was extracted, and converted into dichotomous information yielding the number of patients with at least 50% pain relief. This was then used to calculate the relative benefit and the number-needed-to-treat (NNT) for one patient to achieve at least 50% pain

2000 Cochrane